CervoMed Inc.

CRVO

NASDAQ

Healthcare

Biotechnology

Boston, MA, US15 employeescervomed.com

$4.10

+0.10(2.50%)

Mkt Cap $38M

$3.62

$10.69

52-Week Range

At a Glance

AI-generated

CervoMed Inc.

8-K

CervoMed Inc. issued a press release announcing new analyses from its Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies patients, showing greater clinical benefits in subgroups with lower plasma pTau181 levels indicating absence of Alzheimer’s co-pathology. These data support neflamapimod’s potential mechanism, patient enrichment strategy using pTau181 <21 pg/mL, and 50mg TID dosing for the planned Phase 3 trial.

$38M

Market Cap

$331.5K

Revenue

-$27M

Net Income

Employees15

Fundamentals

How The Business Makes Money

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Industry Biotechnology

Activity

What Changed Recently

of this Current Report on Form 8-K. -- The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Se

of this Current Report on Form 8-K. -- The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Se

of this Current Report on Form 8-K. -- The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Se

of this Current Report on Form 8-K. -- The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Se

of this Current Report on Form 8-K. -- The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Se

Peer Companies

Company	Price	Change	Market Cap	P/E
ADAGAdagene Inc.	$4.05	-12.15%	$153M	-3.8
VTVTvTv Therapeutics Inc.	$41.20	+1.64%	$108M	-11.6
FBIOFortress Biotech, Inc.	$2.56	+3.64%	$79M	20.4
GANXGain Therapeutics, Inc.	$1.84	-4.90%	$78M	-3.4
XBITXBiotech Inc.	$2.35	+0.64%	$72M	-1.6
ACETAdicet Bio, Inc.	$6.98	+1.45%	$67M	-0.4
OSTXOS Therapies Incorporated	$1.37	+0.74%	$48M	—
NTRBNutriband Inc.	$3.75	+4.17%	$46M	-3.6

Analyst View

Company Profile

CIK0001053691

ISINUS15713L1098

CUSIP15713L109

Phone617-744-4400

Address20 Park Plaza, Boston, MA, 02116, US